Cosyntropin Depot Approval Status
Cosyntropin Depot is an alcohol-free, long-acting formulation of a synthetic ACTH analogue in development for use as a diagnostic in the screening of patients presumed to have adrenocortical insufficiency.
Development Status and FDA Approval Process for Cosyntropin Depot
|Dec 20, 2018||Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.